

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
18 May 2017 (18.05.2017)



(10) International Publication Number
WO 2017/083582 A1

(51) International Patent Classification:

A61K 39/395 (2006.01) C07K 16/30 (2006.01)
C07K 16/00 (2006.01) G01N 33/574 (2006.01)

(21) International Application Number:

PCT/US2016/061427

(22) International Filing Date:

10 November 2016 (10.11.2016)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/254,278	12 November 2015 (12.11.2015)	US
62/274,572	4 January 2016 (04.01.2016)	US
62/287,666	27 January 2016 (27.01.2016)	US
62/293,989	11 February 2016 (11.02.2016)	US
62/345,515	3 June 2016 (03.06.2016)	US
62/382,835	2 September 2016 (02.09.2016)	US

(71) Applicant: SIAMAB THERAPEUTICS, INC. [US/US];
90 Bridge Street, Suite 100, Newton, Massachusetts 02458
(US).

(72) Inventors: EAVARONE, David A.; 95 West Squantum
Street, Apt. 1118, North Quincy, Massachusetts 02171
(US). PRENDERGAST, Jillian M.; 18 Park Street,

Maynard, Massachusetts 01754 (US). BEHRENS, Jef-
frey; 48 Wilde Road, Newton, Massachusetts 02468 (US).
LUGOVSKOY, Alexey Alexandrovich; 24 Center Street,
Woburn, Massachusetts 01801 (US). DRANSFIELD,
Daniel T.; 14 George Street, Hanson, Massachusetts 02341
(US).


(74) Agents: WARD, Donna T. et al.; DT WARD, PC, 142A
Main Street, Groton, Massachusetts 01450 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY,
BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR,
KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME,
MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,
OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA,
SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM,
ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ,
TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU,

[Continued on next page]

(54) Title: GLYCAN-INTERACTING COMPOUNDS AND METHODS OF USE



(57) Abstract: The present invention provides glycan-interacting anti-
bodies and methods for producing glycan-interacting antibodies useful
in the treatment and prevention of human disease, including cancer.
Such glycan-interacting antibodies include humanized antibodies, deriv-
atives and fragments thereof as well as related compositions and kits.
Methods of using glycan-interacting antibodies for treatment and dia-
gnosis are included.



TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

— *with sequence listing part of description (Rule 5.2(a))*

Published:

— *with international search report (Art. 21(3))*